Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1069 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2023-09-18 (yahoo.com)
Unpacking the Investment Potential of Charles River Laboratories International Inc (CRL): A ...
Exploring the robust financial stance and growth prospects of Charles River Laboratories International Inc (CRL)
Read more
2022-12-15 (genengnews.com)
Wide Shot: Jacob Glanville Pursues Broad-Spectrum Vaccines vs. Pandemics
In an exclusive interview with GEN Edge, Centivax CEO and president Jacob Glanville, PhD, discusses Centivax’s effort to develop broad-spectrum vaccines for mutating viruses, and the challenges the company has encountered developing them.
Read more
2022-10-04 (finsmes.com)
Wheeler Bio Holds Initial Closing of Series A Funding Round
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Read more
2020-06-01 (abladvisor.com)
Asset Based Lending Industry News, Financial Articles, Blogs, Economic Data, Deal Tables, Company Directories for ABL Professionals
Marathon Asset Management Closes$ 50MM Credit Facility With Baudax Bio Baudax Bio, Inc., a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed on a credit facility of up to$ 50 million from funds
Read more
2016-04-12 (massdevice.com)
Forbion Capital Partners launches $208m life sciences fund
European venture capital shop Forbion Capital Partners said today that it raised a $208 million fund it plans to use for investments in medical device, drug and diagnostic companies. The €183 million fund’ s limited partners included strategic investors Charles River Laboratories and Knight
Read more